Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gamma-aminobutyric acid type A receptor is a ligand-gated chloride channel widely distributed in the central nervous system. It is assembled as a pentameric complex of subunits (most commonly 2α, 2β, 1γ), and upon the binding of its principal endogenous ligand, GABA, the channel opens to allow chloride ions (Cl\(^-\|)) to flow into the neuron. This influx typically hyperpolarizes the neuron, producing an inhibitory effect on neuronal firing and stabilizing network excitability. The GABA\(_A\) receptor is the principal mediator of fast inhibitory synaptic transmission in the brain, and is the target of several classes of clinically important drugs, including benzodiazepines, barbiturates, Z-drugs, and various anesthetics. Alterations in GABA\(_A\) receptor function or expression are linked to a range of neurological and psychiatric disorders, making it a major therapeutic target in medicine and research.
Positive allosteric modulation (benzodiazepines, barbiturates), Direct agonism (GABA, muscimol), Antagonism (bicuculline, picrotoxin), Channel blockade, Negative allosteric modulation
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor (GABA\(_A\) receptor) (GABA\(_A\)R).